This randomized, double-blind, placebo-controlled trial assessed the effects of the oral ghrelin mimetic MK-677 (25 mg daily) on growth hormone (GH) secretion, body composition, and clinical outcomes in 65 healthy adults aged 60–81 over 12 months. MK-677 significantly increased 24-hour mean GH and insulin-like growth factor I (IGF-I) levels to
